Metyrapone
As of the edition of 20 October 2026, Metyrapone is a small molecule: marketed, first approved in 1961 (CH); acts on CYP11B1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Metopirone
- First approved
- 14 June 1961 (CH)
- Approvals on record
- 6 in 5 regions
- Holder of the most recent approval
- Esteve Pharmaceuticals; 5 holders in all
- Registered trials
- 16, 0 stopped early
- Disease areas
- Hormones; Mental health; Nutrition and metabolism; Cancer; Inherited and neonatal; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Metyrapone.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CYP11B1 | Cytochrome P450 11B1, mitochondrial | P15538 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 2 | 0 | 0 |
| Phase 1 | 6 | 5 | 0 | 0 |
| Phase 2 | 3 | 1 | 2 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 3 | 0 | 2 | 0 |
| All trials | 16 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Esteve Pharmaceuticals | Acquired holder | 2025 to now |
| Novartis | Earlier holder |